– Patient screening in Phase 2a study of simufilam in TSC-related epilepsy expected to begin by Q1 2027, following recent lift of FDA clinical hold – Recent publication in Cells1 provides new insights into simufilam’s
Findings provide new insight into simufilam’s effects on cellular stress responses and mitochondrial function New research demonstrates a 37% reduction in elevated ATF4, consistent with attenuation of the
AUSTIN, Texas, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ:FLNA, ", Filana Therapeutics", , the ", Company", )), a biotechnology company currently focused on developing
Patient screening for the Phase 2a study is expected to begin by the first quarter of 2027Filana has engaged a leading clinical research organization, has identified clinical trial sites, and is recruiting potential
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket
AUSTIN, Texas, July 29, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ:FLNA, "Filana Therapeutics", the "Company")), a biotechnology company currently focused on developing therapies for
AUSTIN, Texas, May 07, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ:FLNA, "Filana Therapeutics", the "Company")), a biotechnology company currently focused on developing therapies for Tuberous Sclerosis
AUSTIN, Texas, May 05, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ:FLNA, "Filana Therapeutics", the "Company")), a biotechnology company currently focused on developing therapies for Tuberous Sclerosis
Study in a well-accepted mouse model of severe Tuberous Sclerosis Complex (TSC) showed that simufilam attenuated the progression of seizures in a dose-dependent mannerResults confirm and extend previously published
AUSTIN, Texas, March 12, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (formerly Cassava Sciences, Inc.) (NASDAQ:FLNA, "Filana Therapeutics", the "Company")), a biotechnology company focused on developing novel
New corporate identity reflects the Company's mission to develop novel medicines to modulate filamin A and address unmet needs in treating TSC-related epilepsy Filana Therapeutics to begin trading under "FLNA" effective
